NICE suggests bortezomib, thalidomide for mixed myeloma patients
NICE suggests bortezomib, thalidomide for mixed myeloma patients
The National Institute for Health as well as Clinical Excellence (NICE) has expelled breeze superintendence which recommends a drug bortezomib as well as thalidomide as first-line therapies for a little patients with mixed myeloma, a sort of cancer which affects cells in a bone marrow.